This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
BELLUS Health Inc.
Drug Names(s): ECO-4601
Description: TLN-4601 is a small molecule, natural product derived from a non-pathogenic micro-organism. The preclinical data suggests that TLN-4601 has a novel mechanism of action with dual activity. TLN-4601 is a potent inhibitor of the RAS-mitogen-activated phosphokinase (MAPK) pathway. TLN-4601 acts at the centre of the pathway inhibiting RAS activation, leading to the inhibition of downstream intracellular events. In addition, TLN-4601 also binds selectively to the peripheral benzodiazepine receptor (PBR) that appear to be over-expressed a variety of different tumour types.
Thallion and BELLUS
In June 2013, BELLUS Health and Thallion Pharmaceuticals announced that BELLUS Health has agreed to acquire Thallion for approximately $6.332 million in cash, or $0.1765 per share (on a fully-diluted basis), subject to certain adjustments as described below, and the issuance of contingent value rights (CVRs), which will entitle the holders thereof to additional payments of up to approximately $7.66 million, or $0.2135 per CVR, if certain product revenue milestones are achieved and a future receivable is collected.
In August 2013, BELLUS Health announced the consummation of the previously announced arrangement pursuant to which BELLUS Health has acquired all of the issued and outstanding common shares of Thallion Pharmaceuticals for a purchase price of $6.266 million or $0.1889 per common share, and the issuance of one contingent value right per common share.
Additional information available to subscribers only: